- Albertsons Cos reported an adjusted earnings per share (EPS) of 36 cents for Q2, surpassing the estimated 33 cents but lower than last year’s 44 cents.
- Net sales and other revenue reached $18.89 billion, a slight decline of 0.1% year-over-year, matching the estimate of $18.88 billion.
- The total number of stores decreased by 0.8% to 2,240, slightly below the forecasted 2,241 stores.
- Identical sales fell by 0.8%, compared to a 2.2% increase the previous year, but performed better than the expected decline of 0.97%.
- Digital revenue increased by 11%, slightly missing the expected growth of 11.5%.
- The gross profit margin was reported at 26.8%, down from 27% the previous year, but above the estimate of 26.7%.
- Adjusted EBITDA was $784.0 million, a decrease of 7.6% compared to last year, yet still above the estimated $770.5 million.
- Analyst ratings include 7 buys, 13 holds, and 3 sells.
Albertsons Cos on Smartkarma
Independent analyst coverage of Albertsons Cos on Smartkarma by Baptista Research delves into the company’s recent performance and outlook. In the report titled “Albertsons Companies Reshapes 11 Divisions Into Four Regions — Will Scale Pay Off?“, it is mentioned that the company faced challenges in its core business but saw strong growth in pharmacy and digital segments. Despite a decline in identical store sales by 0.8%, there was a modest underlying increase of approximately 0.7% when excluding certain headwinds. The analysis discusses the impact of macroeconomic factors and industry-wide pressures on Albertsons’ performance.
In another report by Baptista Research titled “Albertsons Companies: A $3.9 Billion EBITDA Signals Resilience Amid Margin Pressure!“, the focus is on the company’s operational resilience amidst industry challenges, particularly in the pharmacy segment. Despite facing headwinds from pharmacy pressures, Albertsons recorded a 0.7% increase in identical sales in the fourth quarter of 2025. The report highlights the positive margin effects due to the structural profitability of generics, showcasing the company’s ability to navigate margin pressures effectively. These insights provide valuable perspectives for investors evaluating Albertsons Cos.
A look at Albertsons Cos Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Albertsons Cos, a retail company that sells food and drug products in the United States, has received various Smart Scores indicating its long-term outlook. With a strong 5 out of 5 score in Dividend, the company shows promise in providing consistent returns to its investors over time. However, its Growth and Resilience scores of 2 reflect potential challenges in expanding and adapting to market changes.
On the other hand, the Value and Momentum scores at 3 suggest a moderate position in terms of financial attractiveness and market performance. Overall, Albertsons Cos seems to offer a stable dividend but may face obstacles in sustaining growth and resilience in the dynamic retail industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
